Log in

Start Your Membership Now

April 23, 2010 The Duke Evidence-based Practice Center presented their evidence report and technology assessment, Preventing Alzheimer's Disease and Cognitive Decline, to the U.S. Department of Health and Human Services. The objective of their work was to assess whether previous research on alleged risk or protective factors for Alzheimer's disease (AD) and cognitive decline is of enough strength to warrant specific recommendations for behavioral, lifestyle, or pharmaceutical modifications targeted to these endpoints. The results of this report were compiled from a total of 25 systematic reviews and 250 primary research studies. The objective, data sources, review . . .

Want To Read More? Log In Or Become A Paid Member
Resource Available For Paid OPEN MINDS Circle Members Only
Not a paid member? Don't miss out! Sign up today and receive unlimited organizational access to all OPEN MINDS strategic advice, market intelligence, and management best practices – over 250,000 resources!
Log In
If you are already a paid member, log in to your account to access this resource and more. If you are a free member, you will need to upgrade to a paid membership before accessing this resource.

Become A Paid Member
If you are not yet a paid member, learn more about the OPEN MINDS Circle Market Intelligence Service Membership on our website, reach out to our team at info@openminds.com, or call us at 877-350-6463.

Market Intelligence Resource | April 23, 2010

Preventing Alzheimer’s Disease and Cognitive Decline: Evidence Report/Technology Assessment

April 23, 2010 The Duke Evidence-based Practice Center presented their evidence report and technology assessment, Preventing Alzheimer's Disease and Cognitive Decline, to the U.S. Department of Health and Human Services. The objective of their work was to assess whether previous research on alleged risk or protective factors for Alzheimer's disease (AD) and cognitive decline is of enough strength to warrant specific recommendations for behavioral, lifestyle, or pharmaceutical modifications targeted to these endpoints. The results of this report were compiled from a total of 25 systematic reviews and 250 primary research studies. The objective, data sources, review . . .

Want To Read More? Log In Or Become A Paid Member
Resource Available For Paid OPEN MINDS Circle Members Only
Not a paid member? Don't miss out! Sign up today and receive unlimited organizational access to all OPEN MINDS strategic advice, market intelligence, and management best practices – over 250,000 resources!
Log In
If you are already a paid member, log in to your account to access this resource and more. If you are a free member, you will need to upgrade to a paid membership before accessing this resource.

Become A Paid Member
If you are not yet a paid member, learn more about the OPEN MINDS Circle Market Intelligence Service Membership on our website, reach out to our team at info@openminds.com, or call us at 877-350-6463.